No profile data available.
Hepion Pharmaceuticals, Inc. (HEPA) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Morristown, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$8.28 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $11.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States.
Hepion Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$11.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Enanta Pharmaceuticals, Inc. (ENTA), Precision BioSciences, Inc. (DTIL), Aligos Therapeutics, Inc. (ALGS), Chemomab Therapeutics Ltd. (CMMB).